Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression

Nana Sasaki(Kyoto Prefectural University of Medicine), Masafumi Taniwaki(Kyoto Prefectural University)
Experimental Hematology
May 12, 2011
Cited by 33


Related Papers